GeNeuro reported earnings results for the fourth quarter and full year ended December 31, 2016. For the fourth quarter of 2016, GeNeuro recognized EUR 1.7 million of revenue from milestone payments from Servier as part of the ongoing clinical trials for its lead therapeutic candidate, GNbAC11, compared to EUR 1.5 million during the fourth quarter of 2015. Full year revenues displayed a strong growth to EUR 6.4 million against EUR 2.5 million for 2015, reflecting the progress of the CHANGE-MS clinical trial. Cash used for operations and investing activities was EUR 16.0 million, of which EUR 5.5 million was for non-recurring items (i.e. EUR 2.5 million for IPO costs, EUR 0.9 million for a milestone payment to bioMérieux for starting the Phase 2b study, EUR 1.1 million for GNbAC1 production costs, EUR 0.3 million of capital expenditures and EUR 0.75 million used by the share liquidity contract).